Rapid Resolution of Post-COVID-19 Inflammatory Syndrome in an Adult With Targeted Inhibition of Interleukin-1B

Mario Felix; Larabe Farrukh; Simple Modi; Ruben Peredo-Wende

doi:10.7759/cureus.32078

Rapid Resolution of Post-COVID-19 Inflammatory Syndrome in an Adult With Targeted Inhibition of Interleukin-1B

Cureus. 2022 Nov 30;14(11):e32078. doi: 10.7759/cureus.32078. eCollection 2022 Nov.

Authors

Mario Felix¹, Larabe Farrukh², Simple Modi³, Ruben Peredo-Wende⁴

Affiliations

¹ Department of Rheumatology, Yale School of Medicine, New Haven, USA.
² Internal Medicine, Albany Medical Center, Albany, USA.
³ Department of Rheumatology, Albany Medical Center, Albany, USA.
⁴ Department of Rheumatology, Albany Stratton VA Medical Center, Albany, USA.

Abstract

Multisystem inflammatory syndrome (MIS) is a severe inflammatory response that occurs days to weeks following the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19). Initially known in children and named MIS-C, recently several cases of MIS in adults have been reported to the Centers for Disease Control and Prevention (CDC), leading to the recognition of a new disease MIS in adults (MIS-A). The current treatment options include high-dose steroids, intravenous immunoglobulin (IVIG), and immunosuppressive therapy. However, the pharmacologic approach remains limited to case reports and pending official guidelines to treat cases with MIS-A. We present a case of an adult patient who had a severe inflammatory state following COVID-19 infection, who was treated with IL-1 antagonist therapy with a successful outcome.

Keywords: acute rheumatology; biologic agents; covid 19; interleukin-1β inhibitor; multisystem inflammatory syndrome in adult.

Publication types

Case Reports